Merestinib |
LY-2801653; 5OGS5K699E,LY2801653 |
Phase Ⅱ |
Lilly |
Solid tumours |
Details
|
SAR-125844 |
SAR-125844,SAR125844 |
Phase Ⅱ |
Sanofi |
Non small cell lung cancer (NSCLC) |
Details
|
JNJ-38877605 |
JNJ-38877605,JNJ38877605 |
Phase Ⅰ |
Johnson & Johnson |
Solid tumours |
Details
|
Telisotuzumab vedotin |
ABBV-399; ABT-399 |
Phase Ⅱ |
Abbvie |
Non small cell lung cancer (NSCLC) |
Details
|
LDC-1267 |
LDC-1267 |
Preclinical |
Max Planck Innovation, Lead Discovery Center |
Cancer |
Details
|
Bozitinib |
CBI-3103; CBT-101;PLB-1001;APL-101 |
Phase Ⅱ |
Heng Kang, CBT, Beijing Pearl Biotechnology, Crown Bioscience |
Glioma, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Solid tumours, Hepatocellular carcinoma (HCC) |
Details
|
LMV-12(HE003) |
LMV-12(HE003) |
Phase Ⅰ |
Helioeast |
Solid tumours |
Details
|
Golvatinib tartrate |
ER-396901-08; E-7050,ER39690108,E7050 |
Phase Ⅱ |
Eisai, QuintilesIMS |
Solid tumours, Hepatocellular carcinoma (HCC), Head and neck cancer |
Details
|
Sitravatinib |
MG-516; MG-91516; MGCD-516 |
Phase Ⅲ |
Mirati Therapeutics, BeiGene |
Non small cell lung cancer (NSCLC) |
Details
|
CBT-101 |
CBT-101 |
Phase Ⅰ |
CBT, Beijing Pearl Biotechnology |
Solid tumours |
Details
|
Amuvatinib |
MP-470; HPK-56,MP470,HPK56 |
Phase Ⅱ |
Astex Pharmaceuticals |
Small cell lung cancer (SCLC) |
Details
|
TAS-115 |
TAS-115,TAS115 |
Phase Ⅰ |
Otsuka, Taiho Pharma |
Solid tumours |
Details
|
SHR-A1403 |
SHR-A1403,SHRA1403 |
Phase Ⅰ |
Jiangsu Hengrui Medicine |
Solid tumours |
Details
|
SAIT-301 |
SAIT-301 |
Phase Ⅰ |
Samsung Medical Center |
Solid tumours |
Details
|
HQP8361 |
APG-8361; HQP-8361; MK-8033,HQP8361 |
Phase Ⅰ |
Merck Sharp & Dohme, Guangzhou Shun Jian Biomedical Technology, Guangzhou Baiyunshan Mingxing Pharmaceutical |
Solid tumours |
Details
|
MK-2461 |
MK-2461 |
Phase Ⅱ |
Merck Sharp & Dohme |
Solid tumours |
Details
|
Recombinant plasmid-hepatocyte growth factor |
Pudk-HGF |
Phase Ⅲ |
Academy of Military Medical Sciences, Wuhan Guanggu Humanwell Healthcare |
Peripheral arterial disease (PAD) |
Details
|
ABT-700 |
ABT-700; h224G11; Mab224G11; Mabh224G11 |
Phase Ⅰ |
Pierre Fabre, Abbvie |
Solid tumours |
Details
|
PF-04217903 |
PF-4217903; PF-04217903; PF-4217903-A ,PF04217903,PF4217903 |
Phase Ⅰ |
Pfizer |
Solid tumours |
Details
|
SGX-523 |
SGX-523,SGX523 |
Phase Ⅰ |
Lilly |
Solid tumours |
Details
|
Golvatinib/Lenvatinib |
|
Phase Ⅱ |
Eisai |
Glioblastoma, Angiomas, Melanoma |
Details
|
Kanitinib |
CX-1003,CX1003 |
Phase Ⅰ |
Beijing Konruns Pharmaceutical, Guangzhou ESA Biotech |
Metastatic prostate carcinoma, Gastroesophageal junction adenocarcinoma |
Details
|
ABN-401 |
ABN-401; KDDF-201603-08 |
Phase Ⅱ |
Abion Inc |
Solid tumours |
Details
|
GST-HG161 |
GST-HG161 |
Phase Ⅰ |
WuXi AppTec, Fujian Cosunter Pharmaceutical |
Hepatocellular carcinoma (HCC) |
Details
|
EMD-1204831 |
EMD-1204831 |
Phase Ⅰ |
Merck Serono |
Solid tumours |
Details
|
Altiratinib |
DCC-22701; DCC-2701; DP-5164; T-678746713 |
Phase Ⅰ |
Deciphera |
Solid tumours |
Details
|
Ningetinib Tosylate |
CT-053-PTSA; CT-053 |
Phase Ⅱ |
HEC Pharm |
Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC), Renal carcinoma |
Details
|
Emibetuzumab |
LA-480; LY-2875358 |
Phase Ⅱ |
Lilly |
Gastric cancer, Non small cell lung cancer (NSCLC) |
Details
|
QBH-196 |
QBH-196 |
Phase Ⅰ |
Shenyang Pharmaceutical University |
Gastric cancer |
Details
|
CM-118 |
CM-118,CM118 |
Phase Ⅰ |
Xcovery, Shanghai Zaixin Pharmaceutical |
Non small cell lung cancer (NSCLC), Malignancies |
Details
|
Boxitinib Hydrochloride |
|
Phase Ⅰ |
HEC Pharm |
Glioma, Gastric cancer, Breast cancer, Lung cancer, Renal carcinoma |
Details
|
HS-10241 |
HS-10241,HS10241 |
Phase Ⅰ |
Hansoh Pharma |
Gastric cancer, Solid tumours, Lung cancer, Liver cancer |
Details
|
Hepapoietin (Atlas Pharmaceuticals) |
APS-1010 |
Phase Ⅱ |
Daiichi Sankyo, Atlas Pharma |
Kidney disorders, Hepatic disorders |
Details
|
Volitinib |
AZD-6094; HMP-504; HMPL-504; HM-5016504 |
NDA Filing |
Hutchison Medipharma, AstraZeneca |
Non small cell lung cancer (NSCLC) |
Details
|
AL-2846 |
AL-2846,AL2846 |
Phase Ⅱ |
Chiatai Tianqing (CTTQ), Nanjing Advenchen Laboratories |
Glioma, Non small cell lung cancer (NSCLC), Gastric cancer, Prostate cancer, Medullary thyroid cancer (MTC), Liver cancer |
Details
|
AMG-208 |
AMG-208,AMG208 |
Phase Ⅱ |
Amgen |
Prostate cancer, Solid tumours |
Details
|
Tivantinib |
ARQ-197 ,ARQ197,ARQ 197 |
Phase Ⅲ |
ArQule, Daiichi Sankyo, Kyowa Hakko Kirin |
Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC) |
Details
|
TPX-0022 |
TPX-0022 |
Phase Ⅰ |
Turning Point Therapeutics |
Solid tumours |
Details
|
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) |
NP-01 |
IND Filing |
Shijiazhuang No.4 Pharmaceutical, Nanjing Nadingfei Medical Technology |
Gastric cancer, Prostate cancer, Lung cancer, Liver cancer |
Details
|
ASLAN-002 |
ASLAN-002; BMS-777607; BMS-797669 |
Phase Ⅱ |
Bristol-Myers Squibb, Aslan |
Gastric cancer, Breast cancer |
Details
|
MCLA-129 |
MCLA-129 |
Preclinical |
Merus, Betta |
Solid tumours |
Details
|
Anti-cMet SIMPLE Antibody |
ARGX-111 |
Phase Ⅰ |
arGEN-X |
Solid tumours |
Details
|
Refanalin |
ANG-3777; BB-3; SNV-003 |
Phase Ⅲ |
Angion Biomedica, sinovant |
Delayed graft function |
Details
|
EM1-mAb DuoBody (Genmab) |
Ab-957 |
Preclinical |
Genmab, Janssen |
Autoimmune diseases |
Details
|
Foretinib |
EXEL-2880; XL-880; GSK-1363089; GSK-089; GSK-1363089G |
Phase Ⅱ |
Exelixis |
Non small cell lung cancer (NSCLC), Breast cancer |
Details
|
LY-3164530 |
LY-3164530 |
Phase Ⅰ |
Lilly |
Solid tumours |
Details
|
Alirinetide |
GM-6; GM-600; GM-602; GM-603; GM-604; GM-605; GM-606; GM-607; GM-608; GM-609 |
Phase Ⅱ |
Genervon |
Amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Ischemic stroke |
Details
|
DBPR-114 |
|
Phase Ⅰ |
National Health Research Institutes |
Cancer |
Details
|
BMS-794833 |
BMS-794833,BMS794833 |
Preclinical |
Bristol-Myers Squibb |
Solid tumours |
Details
|
EMB-01 |
EMB-01 |
Phase Ⅱ |
EpimAb Biotherapeutics |
Solid tumours |
Details
|
Metatinib Trometamol |
BMS-817378; SIM-817378 |
Phase Ⅰ |
Bristol-Myers Squibb, Simcere |
Non small cell lung cancer (NSCLC), Gastric cancer, Metastatic colorectal cancer (CRC), Liver cancer |
Details
|
[18F]-AH113804 |
[18F]-AH113804 |
Preclinical |
GE Healthcare |
Diagnostic agents |
Details
|
EMD-94283 |
EMD-94283 |
Phase Ⅰ |
Merck Serono |
Cancer |
Details
|
Amivantamab |
JNJ-61186372; JNJ-372 |
Phase Ⅲ |
Genmab, Janssen |
Non small cell lung cancer (NSCLC) |
Details
|
Onartuzumab |
OA-5D5; PRO-143966; RG-3638; RO-5490258,OA5D5,PRO143966,RG3638,RO5490258 |
Phase Ⅲ |
Genentech, Chugai |
Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Solid tumours, Colorectal cancer, Hepatocellular carcinoma (HCC), Glioblastoma |
Details
|
Glumetinib |
HH-SCC244; SCC244 |
Phase Ⅱ |
Shanghai Institute of Materia Medica, Shanghai Green Valley Pharmaceutical, Haihe Biopharma |
Non small cell lung cancer (NSCLC) |
Details
|
SPH3348 |
SPH-3348 |
Phase Ⅰ |
Shanghai Pharma |
Gastric cancer, Lung cancer, Liver cancer |
Details
|
XL-092 |
XL-092 |
Phase Ⅰ |
Exelixis |
Cancer |
Details
|
Sym-015 |
Sym-015 |
Phase Ⅱ |
Symphogen |
Lung cancer |
Details
|
RXDX-106 |
RXDX-106 |
Phase Ⅰ |
Teva, Daiichi Sankyo, Roche |
Solid tumours |
Details
|
AMG-337 |
AMG-337,AMG337 |
Phase Ⅱ |
Amgen, NantPharma, Astellas |
Gastric cancer, Esophageal adenocarcinoma, Solid tumours |
Details
|
Glesatinib |
MGCD-265; MG-90265; MG-90265H9; MG-90265X; MG-90265gly; 7Q29OXD98N,MGCD265 |
Phase Ⅱ |
Mirati Therapeutics |
Non small cell lung cancer (NSCLC), Solid tumours |
Details
|
Recombinant human hepatocyte growth factor (Kyoto University) |
|
Phase Ⅱ |
Kyoto University |
Liver failure |
Details
|
JNJ-38877618 |
JNJ-38877618; OMO-1 |
Phase Ⅱ |
Johnson & Johnson |
Solid tumours |
Details
|
MK-8033 |
MK-8033,MK8033 |
Phase Ⅰ |
Merck Sharp & Dohme |
Solid tumours |
Details
|
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) |
|
Phase Ⅰ |
The Second Hospital of Nanjing Medical University |
Primary hepatocellular carcinoma |
Details
|
BPI-9016 |
BPI-9016M; BPI-9016 |
Phase Ⅰ |
Betta |
Non small cell lung cancer (NSCLC) |
Details
|
S-49076 |
S-49076,S49076 |
Phase Ⅱ |
Servier |
Non small cell lung cancer (NSCLC), Glioblastoma |
Details
|